Literature DB >> 1737357

Ploidy and specific karyotypic changes during promotion with phenobarbital, 2,5,2',5'-tetrachlorobiphenyl, and/or 3,4,3'4'-tetrachlorobiphenyl in rat liver.

L M Sargent1, G L Sattler, B Roloff, Y H Xu, C A Sattler, L Meisner, H C Pitot.   

Abstract

Polychlorinated biphenyls are a group of industrial chemicals that are widely distributed in the environment. Since these compounds occur as mixtures, studies of their possible interactive effects are important. In order to determine whether an interaction of 2,5,2',5'-tetrachlorobiphenyl (TCB) with 3,4,3',4'-TCB occurs during multistage hepatocarcinogenesis in vivo, like that previously observed in lymphocytes in vitro (L. M. Sargent et al., Mutat. Res., 224: 79-88, 1989), we exposed rats to a single initiating dose of diethylnitrosamine (DEN), 10 mg/kg after a 70% partial hepatectomy, and subsequently to 0.1 ppm 3,4,3',4'-TCB and/or 10 ppm 2,5,2',5'-TCB in the diet for 1 year. Administration of each of the TCBs alone after DEN initiation resulted in a low incidence of chromosomal damage in hepatocytes; but when the two were given together after DEN initiation, there was a more than additive effect on this parameter at both 7 and 12 months which was highly significant. Administration of the TCBs alone or in combination in the absence of DEN initiation also resulted in chromosomal damage, approaching that seen in livers of animals initiated with DEN when sacrificed at 12 months. In animals receiving 0.05% phenobarbital for a 12-month period after initiation with DEN, a significant degree of chromosomal breakage and fragment formation occurred both in hepatocytes expressing the ectoenzyme gamma-glutamyltranspeptidase (GGT) and in those that were GGT negative. However, the GGT-negative cells showed a significantly lower incidence of chromosomal damage than the GGT-positive hepatocytes. Exposure to phenobarbital for 7 months after DEN initiation resulted in no significant chromosomal damage in hepatocytes, whether GGT positive or GGT negative. Some degree of specificity in chromosomal alterations was seen in hepatocytes of animals initiated with DEN and promoted either with a combination of TCBs or with phenobarbital. The most frequent alterations seen were a trisomy of chromosome 1 or of its long arm and a monosomy of chromosome 3 or its short arm. Some chromosome 7 aberrations were also seen. The highest frequency of specific aberrations occurred in hepatocytes from rats that also bore hepatocellular carcinomas, suggestive of the hypothesis that genes involved in the development of hepatic carcinoma may reside in chromosome 1 and/or 3 of the rat.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737357

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Polychlorinated Biphenyl (PCB) carcinogenicity with special emphasis on airborne PCBs.

Authors:  Larry W Robertson; Gabriele Ludewig
Journal:  Gefahrst Reinhalt Luft       Date:  2011-01       Impact factor: 0.323

2.  Chromosome survey of seals in the Baltic Sea in 1988-1992.

Authors:  K Hongell
Journal:  Arch Environ Contam Toxicol       Date:  1996-10       Impact factor: 2.804

Review 3.  Polychlorinated biphenyls (PCBs) as initiating agents in hepatocellular carcinoma.

Authors:  Gabriele Ludewig; Larry W Robertson
Journal:  Cancer Lett       Date:  2012-12-02       Impact factor: 8.679

4.  Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway.

Authors:  Keigo Machida; Jian-Chang Liu; George McNamara; Alexandra Levine; Lewei Duan; Michael M C Lai
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

5.  Polychlorinated-biphenyl-induced oxidative stress and cytotoxicity can be mitigated by antioxidants after exposure.

Authors:  Yueming Zhu; Amanda L Kalen; Ling Li; Hans-J Lehmler; Larry W Robertson; Prabhat C Goswami; Douglas R Spitz; Nukhet Aykin-Burns
Journal:  Free Radic Biol Med       Date:  2009-09-28       Impact factor: 7.376

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.